Patient access to medicines: how to prevent medicine shortages?

Brussels
6th December 2017
Patient access to medicines: how to prevent medicine shortages?

Marc-Alexander Mahl
Brussels, 06 December 2017
Reports about medicine shortages in Europe

Drug Shortages Continue to Vex Doctors

By SABRINA TAVERNSIE, FEB 03, 2014

Despite efforts by the Obama administration to ease shortages of critical drugs, shortages have persisted, forcing doctors to resort to rationing in some cases or to scramble for alternatives, a government watchdog agency said Monday. The number of airport delays — both new and continuing ones — nearly tripled from 2007 to 2012.

A Vital Drug Runs Low, Though Its Base Ingredient Is in Many Kitchens

By KATIE THOMAS, MAY 21, 2017

Hospitals around the country are scrambling to stockpile vials of a critical drug — even postponing operations or putting off chemotherapy treatments — because the country’s only two suppliers have run out.

The medicine? Sodium bicarbonate solution. Yes, baking soda.

Sodium bicarbonate is the simplest of drugs — its base ingredient, after all, is found in most kitchen cabinets — but it is vitally important for all kinds of patients whose blood has become too acidic. It is found on emergency crash carts and is used in open-heart surgery and as an antidote to certain poisons. Patients whose
Why are there multisource medicine shortages?

**THE EVIDENCE** that the root cause of medicines shortages are economic, including unsustainable P&R policies, is overwhelming.

- **Study**
  - Kweder 2013
  - "It is time for healthcare systems to recognize that such costs and economic drivers are essential elements”

- **Proximate Causes**
  - Pauwels 2014
  - "Cost-containment measures need to be applied with scrutiny to ensure that all players of the drug supply chain can undertake their activities in a sustainable way.”

  - De Weerdt 2015
  - "For generic medicines, internal or external reference pricing, tendering as well as price capping may affect drug shortages”
Generic medicines manufacturers offer maximum benefit to patients

Generic medicines manufacturers operate cost efficiently to deliver patient benefits

- **Generic drug competition is fierce** - Average price reduction after patent expiry **50%, increasing** over time
- Generic manufacturing is a **high-volume / low-margin** business (MS: 29% in value / 62% in volume)
- A single manufacturer can have **25 000** market authorizations in Europe
- **350 European** manufacturing facilities
- Complex supply chains for cost and flexibility (many supply chain partners)
- A manufacturer can ship to **50 000+** customers in Europe

- **R&D investment** to bring new devices, formulations and biosimilars to bring competition and access to specialty markets

Source: Medicines for Europe members survey
Regulatory compliance impacts cost structure

- Large manufacturer employ **up to few hundred** people in regulatory and Pharmacovigilance to cover Europe

- **More than 50% of Regulatory Activities** dedicated to dossier maintenance only

- **75% of EU regulatory budget** on **MA maintenance cost** e.g. renewals, Annual fees, PSUR’s, Safety Variations, CMC Variations

*Source: Medicines for Europe Regulatory Efficiency Report 2015*
The ability to supply negatively affected by:

- Regulatory costs
- Price pressure & tender rules

**Regulatory compliance**
- Falsified Medicines Directive
- GMP / GCP /...
- Variations, notification
- Pharmacovigilance regulation

**Price & tender rules**
- Tendering (single-winner tenders, unbalanced penalties, lead-times, ...)
- External Reference Pricing
- Price cuts
- Claw-back taxation
PORTUGAL: DRAMATIC REDUCTION IN HOSPITAL SUPPLIERS DUE TO PAYBACK

<table>
<thead>
<tr>
<th>Código SPMS</th>
<th>Artigo SPMS</th>
<th>Nº Contrato Público</th>
<th>Número AIMS</th>
<th>Número Empresas SPMS</th>
<th>variação</th>
</tr>
</thead>
<tbody>
<tr>
<td>G128</td>
<td>GLUCOSE 5% [20ML]</td>
<td>2012003</td>
<td>7</td>
<td>2</td>
<td>-5</td>
</tr>
<tr>
<td>A467</td>
<td>AMOXICILINA + ÁCIDO CLAVULANICO [2000 + 200 MG; IV; F/AMP]</td>
<td>2013005</td>
<td>10</td>
<td>5</td>
<td>-5</td>
</tr>
<tr>
<td>A466</td>
<td>AMOXICILINA + ÁCIDO CLAVULANICO [1000 + 200 MG; IV; F/AMP]</td>
<td>2013005</td>
<td>7</td>
<td>5</td>
<td>-2</td>
</tr>
<tr>
<td>C120</td>
<td>CEFТАZIDIMA [1G; IM-IV; F/AMP]</td>
<td>2013005</td>
<td>11</td>
<td>2</td>
<td>-9</td>
</tr>
<tr>
<td>C121</td>
<td>CEFТАZIDIMA [2G; IV; F/AMP]</td>
<td>2013005</td>
<td>12</td>
<td>2</td>
<td>-10</td>
</tr>
<tr>
<td>C1447</td>
<td>CEFUROXIMA [750 MG; IV; F/AMP]</td>
<td>2013005</td>
<td>5</td>
<td>2</td>
<td>-3</td>
</tr>
<tr>
<td>F128</td>
<td>FLUCLOXACILINA [500MG; IM-IV; F/AMP]</td>
<td>2013005</td>
<td>6</td>
<td>2</td>
<td>-4</td>
</tr>
<tr>
<td>M56</td>
<td>MEROPENEM [500 MG; IV; F/AMP]</td>
<td>2013005</td>
<td>17</td>
<td>5</td>
<td>-12</td>
</tr>
<tr>
<td>M55</td>
<td>MEROPENEM [1G; IV; F/AMP]</td>
<td>2013005</td>
<td>17</td>
<td>4</td>
<td>-13</td>
</tr>
<tr>
<td>P116</td>
<td>PIPERACILINA + TAZOBACTAM [4 + 0,5G ;IV; F/AMP]</td>
<td>2013005</td>
<td>13</td>
<td>5</td>
<td>-8</td>
</tr>
<tr>
<td>D459</td>
<td>DOCETAXEL (CONC P/A SOL) [20 MG/1 ML; FRS]</td>
<td>2013006</td>
<td>10</td>
<td>3</td>
<td>-7</td>
</tr>
<tr>
<td>G46</td>
<td>GEMCITABINA [PO P/ SOL P/ PERF] [200MG; FRS]</td>
<td>2013006</td>
<td>16</td>
<td>2</td>
<td>-14</td>
</tr>
<tr>
<td>G256</td>
<td>GEMCITABINA [40 MG/ML; 5 ML; SOL INJ; FRS]</td>
<td>2013006</td>
<td>11</td>
<td>2</td>
<td>-9</td>
</tr>
<tr>
<td>G254</td>
<td>GEMCITABINA [40 MG/ML; 25 ML; CONC P/ SOL P/ PERF; FRS]</td>
<td>2013006</td>
<td>11</td>
<td>2</td>
<td>-9</td>
</tr>
<tr>
<td>P2</td>
<td>PACITAXEL (CONC P/ SOL P/ PERF)[6 MG/ ML; 5 ML; FRS]</td>
<td>2013006</td>
<td>7</td>
<td>4</td>
<td>-3</td>
</tr>
<tr>
<td>PB35</td>
<td>PACITAXEL (CONC P/ SOL P/ PERF) [6 MG/ML; 16,7 ML; FRS]</td>
<td>2013006</td>
<td>7</td>
<td>4</td>
<td>-3</td>
</tr>
<tr>
<td>A15</td>
<td>ACARBOSE [50MG; CÁP/COMP]</td>
<td>2013007</td>
<td>15</td>
<td>5</td>
<td>-10</td>
</tr>
<tr>
<td>M910</td>
<td>METFORMINA [1000 MG; CÁP/COMP]</td>
<td>2013007</td>
<td>22</td>
<td>5</td>
<td>-17</td>
</tr>
<tr>
<td>O5</td>
<td>OCTREOTIDA [50MCG/1ML; F/AMP]</td>
<td>2013007</td>
<td>8</td>
<td>1</td>
<td>-7</td>
</tr>
<tr>
<td>M246</td>
<td>MIRTAZAPINA [30 MG; CÁP/COMP]</td>
<td>2013044</td>
<td>23</td>
<td>3</td>
<td>-20</td>
</tr>
<tr>
<td>M1104</td>
<td>MIRTAZAPINA [15 MG;COMP ORDISP]</td>
<td>2013044</td>
<td>15</td>
<td>5</td>
<td>-10</td>
</tr>
<tr>
<td>P396</td>
<td>PARACETAMOL [1 G; IV; F/AMP]</td>
<td>2013044</td>
<td>16</td>
<td>2</td>
<td>-14</td>
</tr>
<tr>
<td>T143</td>
<td>TRAMADOL [100MG/2ML/AMP]</td>
<td>2013044</td>
<td>7</td>
<td>2</td>
<td>-5</td>
</tr>
<tr>
<td>C224</td>
<td>CISATRACURIO (Besilato)[5 MG/2,5ML/AMP]</td>
<td>2013045</td>
<td>7</td>
<td>2</td>
<td>-5</td>
</tr>
<tr>
<td>I4</td>
<td>IBUPROFEND [200MG; CÁP/COMP]</td>
<td>2013047</td>
<td>12</td>
<td>5</td>
<td>-7</td>
</tr>
</tbody>
</table>
EXAMPLE OF PRICE PRESSURE

ROMANIA:
2000 MEDICINES WITHDRAWN!

• External reference pricing and clawback tax reduce access to medicines

• European Commission (DG ECFIN): ‘Joint Report on Health Care and Long-Term Care Systems & Fiscal Sustainability’

“While overspending is recovered via the claw-back tax (...), it has led to withdrawals of generic medicines from the market”.

EXAMPLE OF PRICE PRESSURE

THE NETHERLANDS: 69% permanent shortages have an \emph{economical} cause

Presentation Marcel van Raaij, Ministry of Health in the Netherlands; Joint Conference IGBA, Medicines for Europe Lisbon 2017
Thank you.
Lieve Wierinck
Agnès Mathieu
Patient access to medicines: how to prevent shortages

Conference organised by Medicines for Europe

Brussels, 6 December 2017

Agnès Mathieu
Deputy Head of Unit
European Commission
Unit B4. Medical products: quality, safety, innovation
DG Health and Food Safety
Context

- Availability/shortage: important problem with serious consequences for health and sustainability of healthcare

- Driven by manufacturing problems or economic reason

- Affects all products, including cytotoxic, vaccines, blood based medicines
Call from the European Parliament

Report on access to medicines with recommendations on shortages of medicines:

- formulate a better definition, to assess the impact of parallel trade and supply quotas, to establish and update together with the Member States, the EMA and relevant stakeholders a list of essential medicines, ...to monitor compliance with Article 81 of Directive 2001/83/EC on shortages of supply, to explore mechanisms to address the withdrawal of effective medicines from the market purely for commercial reasons, and to take actions to remedy these shortages;

- establish a mechanism whereby medicine shortages across the EU can be reported upon on an annual basis;

...
Call from the Council

• SK Presidency made "shortages of medicines" a priority for its presidency.
• Working Party on Public Health at Senior level on 15 July 2016 and the informal Health Council on 3-4 October, all Member States agreed that the topic deserves action at EU level.
HMA/EMA Task force on availability

- Theme 1: Marketing of authorised medicinal products

- Theme 2 - Supply Chain Disruption
Shortages: Legal Tools (Dir. 2001/83/EC) (I) Member States' competence

- Article 81 obliges MAH and WD to ensure appropriate and continued supplies so that the needs of patients are covered (within the limits of their responsibilities).

- Article 23a obliges the MAH ceasing production to communicate all data relating to the volume of sales and prescriptions of the medicinal product to the competent authorities so to give advance notice of potential shortages.

- Article 126a enables MS to authorise a medicinal product for which there is no marketing authorisation - for public health reasons and if already authorised in another MS.
Shortages: Legal Tools (Dir. 2001/83/EC) (II)

- Article 63(3) allows, in case of shortages, to waive some of the labelling requirements, thus facilitating the placing on the market of alternative sources.

- Article 5.1 allows the use of unauthorised medicinal products "to fulfil special needs" and for use by an individual patient under direct responsibility of a doctor.
Shortages due to parallel trade

• Parallel export: legal form of trade whereby medicinal products are exported to other Member States to benefit from arbitrage

• The Court recognised that in cases where parallel trade would effectively lead to a shortage of medicines on a given national market, national authorities may take action to resolve the situation, by taking appropriate and proportionate steps that are consistent with the obligations flowing from Article 81 of Directive 2001/83 and with the Treaty (TFEU) rules.
What will be done by the Commission

- EC cannot prevent the withdrawal of a product from the market but an obligation of continuous supply exists if the product is placed on the market
- EC supports the Member States through a project on exchange of best practices
- Close cooperation with the EMA/HMA task force on availability
- Member States have to reply to the enquiry by 5 December 2017 (results available in 2018)
- Databases from the falsified medicines could help in the future
- Generics could diversify the offer of medicines
Thank You
patients • quality • value • sustainability • partnership

Cristian-Silviu BuȘoi
Our panel today

- **Ortwin SCHULTE**, Head of Health Policy Unit, German Permanent Representation
- **Eddy GILISSEN**, VP Supplier Alliances, IQVIA
- **Vlad VOICULESCU**, Member of Romanian Health Observatory, Romania
- **Elfi DE WEERDT**, PhD medicine shortages, KU Leuven, Belgium
Ortwin Schulte
Eddy Gillissen
Medicine shortages and correlation with economic causes

6th December 2017

Eddy Gilissen
VP Supplier Alliances NEMEA
The issue of shortages is still very current

Europe needs a plan to combat cancer drug shortages, says report
PharmaPhorum, 18-May-17

Are low generics prices at risk of causing shortages and sudden spikes?
The Pharma letter, 24-Nov-17

Healthcare Groups Urge Congressional Action on Drug Shortages
Increased Transparency, Improvements to Manufacturing Infrastructure Needed
Newswise, 10-Nov-17

How to cope with medicine shortages in a cut-throat market
Pharmacy News, 23-Nov-17

China Focus: China moves to address shortages in life-saving medicines
Source: Xinhua | 2017-11-22 20:12:02 | Editor: liuxin

Drug shortages: it’s time for Europe to act
The Pharmaceutical Journal, 29-Jan-15
There are different factors which can cause shortages in the market:

- Diversion due to parallel export in some selected markets
- Shortage of raw materials
- Manufacturing issues
- Lack of production capacity due to unforeseen demand
- Downwards price spiral due to tendering systems
- Manufacturers leave the market for economic reasons

Underlying causes of shortages
The majority of European hospital pharmacists believe medicine shortages are a problem

*Antimicrobials and Oncology are the categories with the highest shortages reported*

Proportion of hospital pharmacists (%) stating that medicines shortages are a current problem in their country. N=537

Category of shortages reported overall. N=418

Source: European Journal of Hospital Pharmacy, October 2014; N = number of hospital pharmacists in 36 European countries who responded to a question in the EAHP’s 2014 survey
Lack of competition can make markets more susceptible to shortages and have a negative impact on prices

Case study:
- Amoxicillin
- ATC4: J1C1 (BRD.SPECT.Penicill.ORAL)
- NFC123: DGJ (DRY SYRUP/DROP)

- In Denmark and Sweden, there are only a few manufacturers which produce this form of Amoxicillin, which makes these markets more susceptible to shortages.
- With only a few providers left in Denmark and Sweden, a monopoly situation has been established, and prices have risen because of lack of competition.
- In Spain, there are several more manufacturers of this molecule in the market, and as a result, the price of the product has remained low.

<table>
<thead>
<tr>
<th>Country</th>
<th>Manufacturer</th>
<th>QTR_09_2012</th>
<th>QTR_09_2016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Sales mnf (LC_EUR)</td>
<td>Standard Units</td>
</tr>
<tr>
<td>Denmark</td>
<td>MEDA AS</td>
<td>107370</td>
<td>342605</td>
</tr>
<tr>
<td>Sweden</td>
<td>MEDA</td>
<td>70674</td>
<td>143528</td>
</tr>
<tr>
<td></td>
<td>MYLAN</td>
<td>391</td>
<td>1650</td>
</tr>
<tr>
<td></td>
<td>Sandoz Gmbh</td>
<td>5051</td>
<td>8192</td>
</tr>
<tr>
<td>Spain</td>
<td>Aristo Pharma Iber</td>
<td>6750</td>
<td>110208</td>
</tr>
<tr>
<td></td>
<td>Bohm</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Gsk</td>
<td>31237</td>
<td>509948</td>
</tr>
<tr>
<td></td>
<td>Normon</td>
<td>329368</td>
<td>5021724</td>
</tr>
<tr>
<td></td>
<td>Sandoz Farmaceutic</td>
<td>108301</td>
<td>1768176</td>
</tr>
<tr>
<td></td>
<td>Quimifar</td>
<td>4067</td>
<td>62544</td>
</tr>
<tr>
<td></td>
<td>Reig Jofre</td>
<td>57962</td>
<td>876144</td>
</tr>
<tr>
<td></td>
<td>MundoGen Farma</td>
<td>21830</td>
<td>356400</td>
</tr>
<tr>
<td></td>
<td>Vir</td>
<td>67</td>
<td>420</td>
</tr>
</tbody>
</table>

Source: IMS Health MIDAS QTR 09 2016
Drug shortages are becoming more common in the Netherlands. In 2016, 710 medicines were not available. In 2015, these were more than 625 medicines.

Every month pharmacists have to look for alternative medication for 580,000 prescriptions due to shortages; this doesn’t mean that the molecule could not be available, but the “preferential” product isn’t. In many cases, due to low market attractiveness resulting from the tendering system, alternative providers haven’t stayed in the market.

In 70% of cases, pharmaceuticals are completely withdrawn from the market for economic reasons. Simple, relatively cheap medicines regularly disappear from the Dutch market because drug prices are so low here. Combined with the low population and low drug consumption, the low prices can make the Netherlands a relatively unattractive market.

- Temporary drug shortages often arise due to production problems or due to increased demand.
- Final drug shortages are when pharmaceuticals are completely withdrawn from the market.

Source: KNMP: Professional and trade association for pharmacists, Netherlands
Significant price drops carry a high risk potential for shortages

Reported shortages in the supply of antibiotic agents is particularly common in the in-patient (hospital) sector in Germany.

In the in-patient sector, an increasing number in suppliers or less market concentration reduces the risk of shortages in supply.

However, **dramatically decreasing prices despite higher requirements for production** (high percentage of parenteral solutions) carry a high risk potential.
The dependence on imports of intermediates and APIs leads to supply shortages of (generic) antibiotics in Germany

Causes for Supply shortages of Antibiotic intermediates and API’s in Germany:

**Increasing concentration of foreign producers of intermediates and APIs, especially in China and India**

- **Only few suppliers are available** due to a high market concentration.
- **Growing quality requirements** for local production plants, which cannot be fulfilled by all manufacturers.
- **Expensive “multiple sourcing”** not feasible for German antibiotics producers due to cost pressure, thus lack of alternative suppliers in case of supply shortages.

**Production deficiencies of foreign manufacturers**

- **Operational problems in the production process** of intermediates and APIs, which may lead to delays in the supply.
- **Quality deficiencies** of imported intermediates and APIs, thus uselessness of delivered products.

API = Active Pharmaceutical Ingredient

Source: Roland Berger, January 2017
Lack of production capacity can result from unforeseen demand or production or quality problems

Flu Vaccines

• In 2013, in US Roche had a temporary shortage of the liquid version of Flu vaccine, Tamiflu, given to children, because of over demand and supply issue

• In the same year in the US, Sanofi SA, the largest flu vaccine provider in the United States, said on Thursday it had sold out of four of the six different dosages of Fluzone seasonal flu vaccine due to unanticipated demand.

Heparins

• In 2008, major recalls of heparin were announced by the FDA due to contamination of the raw heparin stock imported from China.

• This contaminated heparin caused the death of 81 people and 785 reports of serious injuries.

• This changed the regulation and the enforcement actions against API manufacturers.
Conclusions

- There are a few main underlying causes of shortages in Europe, grouped into economic, business and supply chain.

- Shortages can be split into short-term and long-term shortages:
  › Short-term, usually local shortages, which can arise because distribution problems.
  › More serious long-term shortages at a national level may also result from important price drops and high differences in pricing between countries.

- When prices drop so low that the number of providers becomes very limited, this has implications on the sustainability of our healthcare system and the provision of pharmaceuticals. This is not only an issue for the pharmaceutical manufacturers, but also for the wholesalers and the pharmacists who have to be available to provide medicines for the patients.

- Dependence on non-EU imports can increase risk of supply issues

- The impact on patients is difficult to quantify, but existing. An equal effective alternative should be available, what is not always the case today. A drastic change in their treatment pattern could lead to side effects and errors and a reduction of adherence and compliance levels. In cases where there is no alternative available, or the alternative is ineffective, the disease can resume.
Looking forward to the solutions!
eddy.gilissen@iqvia.com
Elfi De Weerdt
Causes of drug shortages

Medicines for Europe – 6/12/2017

Elfi De Weerdt
PhD-researcher

Supervisor: prof. Isabelle Huys
Co-supervisors: prof. Steven Simoens
prof. Minne Casteels
Chapter 1: Definition of drug shortages

Chapter 2: Influence of legal framework on drug shortages

Chapter 3: In-depth database analyses on reported drug shortages in EU

Chapter 4: Economic impact of drug shortages in hospital pharmacies

Chapter 5: Economic impact of drug shortages in community pharmacies

Chapter 6: Clinical and economic impact of drug shortages on patients

Chapter 7: Measures to prevent drug shortages across EU

Chapter 8: Measures to manage drug shortages across EU

Chapter 9: Recommendations towards preventing and mitigating drug shortages
Causes of drug shortages described in literature

Review on legal framework causing drug shortages

Aim

• Causes of drug shortages in legal pharmaceutical framework?

Methodology

• Review of European legislations
• Review of national legislations
• Review in published literature
Causes in the legal pharmaceutical framework

**Patented drugs**

- Price settings
  - External reference pricing

- Reimbursement procedures

**Generic drugs**

- Price settings
  - Tendering
    - Manufacturers → vulnerable market for drug shortages
  - Price capping
    - Price → no incentive for manufacturers
  - Internal reference pricing

Causes in the legal pharmaceutical framework

Parallel trade

• Key concept = free movement of goods

• Quota
  o Back-up system

Manufacturing and quality requirements

• GMP Directive
  o Audits
  o Safety, effective and quality
  o Active pharmaceutical ingredient + drug manufacturers

• Falsified Medicines Directive
  o Import of API

• Quality requirements
  o Labelling, leaflet

Causes in the legal pharmaceutical framework

Withdrawal of market authorization

• Pharmaceutical company
  o Business decisions
    • Portfolios adjusted: looking for higher margin options
    • No incentive for sustainable production
  o Change of drug status
    • Prescription → OTC

• Competent authorities
  o Ultimate measure

Conclusions

- Pricing procedures and quality requirements seem to strengthen each other in causing drug shortages
  - Price regulated by authorities, not by company
  - Quality is mandatory by law
    - Companies want to deliver high quality drugs

Manufacturers will leave markets when profit-margins for generic drugs decrease.

⇒ Need for balance between quality requirements and prices of drugs

ISPE 2017 - Drug Shortages: An exploration of the relationship between U.S. market forces and sterile injectable pharmaceutical products: Interviews with 10 pharmaceutical companies
COST Action: medicine shortages*

- European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe

- COST does not fund research itself, but provides support for networking activities carried out within COST Action

- Involvement of:
  - National health authorities, universities, EAHP, EURORDIS, medical doctors, *etc.*

- *Prof. Huys is lead of work package 1: landscape of drug shortages*
Q&A
‘Patient access to medicines: how to prevent medicine shortages?

Marc-Alexander Mahl
Brussels, 06 December 2017
CREATING AND MAINTAINING A MULTI-SOURCE MARKET

**PREVENT SHORTAGES**
- Improve regulatory efficiency to reduce administrative and cost burden of keeping products in the market
- Ensure market predictability
- Address negative impact of parallel trade
- Manage available market stock information

**MITIGATE SHORTAGES**
- Specific regulatory measures to mitigate imminent medicine shortages

MORE MANUFACTURERS = LESS SHORTAGES
TACKLING SHORTAGE IN THE OFF-PATENT SECTOR

- Multi-source markets with healthy competition can prevent medicines shortages.
- Shortages risk increases when market relies on small number of manufacturers.
- Price cuts/pricing mechanism such as tendering and increasing regulatory costs reduce incentives for introducing or maintaining generic product in the market.
- Parallel trade is not the main cause of generic medicines shortages.
- Penalties increase the risk for MAH, reducing incentives to maintain products in the market.
- Aligned communication between authorities and MAH can help to prevent shortages.
- Continuous dialogue between MAH and NCA to validate solutions is required.
Thank you!
Patient access to medicines: how to prevent medicine shortages?

Brussels
6th December 2017